Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply

JAMA. 2022 May 24;327(20):2020-2021. doi: 10.1001/jama.2022.5134.

Authors

Matthew E Oster¹, David K Shay², Tom T Shimabukuro²

Affiliations

¹ Centers for Disease Control and Prevention, Children's Healthcare of Atlanta, Atlanta, Georgia.
² COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia.

PMID: 35608588
DOI: 10.1001/jama.2022.5134

No abstract available

Publication types

Comment

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19 Vaccines* / therapeutic use
COVID-19* / epidemiology
COVID-19* / prevention & control
Humans
Myocarditis* / chemically induced
Myocarditis* / epidemiology
Myocarditis* / etiology
RNA, Messenger
United States / epidemiology
Vaccination / adverse effects
Vaccination / statistics & numerical data
Vaccines, Synthetic* / adverse effects
Vaccines, Synthetic* / therapeutic use
mRNA Vaccines* / adverse effects
mRNA Vaccines* / therapeutic use

Substances

COVID-19 Vaccines
RNA, Messenger
Vaccines, Synthetic
mRNA Vaccines